You searched for "oedema"
Inflammatory macular holes
The authors present a case of closure of a full thickness macular hole in a patient with Behçet’s disease, without surgery. The 23-year-old male they describe presented with a history of recurrent oral aphthous ulcers and a genital ulcer. Ocular...
Unique case of steroid-induced intraocular pressure spike causing NAION
The literature describes previous cases of nonarteritic anterior ischaemic optic neuropathy (NAION) following rapid rises in intraocular pressure (IOP) leading to reduced optic nerve head perfusion and disruption. This is commonly following ophthalmic procedures, acute glaucoma or steroid eye drops....
Microsporidia-induced stromal keratitis: a new cause of presumed immune stromal (interstitial) keratitis
This is a non-comparative retrospective observational case series from India from 1 October 2020 to 31 January 2021. The inclusion criteria were: (1) presence of nummular / coin shaped lesions with at least one >2mm in size and / presence...Papilloedema: an update
Some readers may have seen a recent report in the national newspapers of the case of a teenage girl with persistent severe headache associated with a fatal brain tumour having been undiagnosed despite many consultations with her medical advisers. It...Vabysmo receives NICE approval
The National Institute for Health and Care Excellence (NICE) has recently approved Vabysmo▼(faricimab) for treating adults with visual impairment due to macular oedema secondary to branch and central retinal vein occlusion (BRVO and CRVO). The NICE approval of Vabysmo was...
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
Adjuvant intravitreal dexamethasone implant for persistent CME
In this retrospective, cross-sectional study the authors investigate the efficiency of intravitreal dexamethasone implants (0.7mg) for cystoid macular oedema (CME) persisting, despite immunomodulatory treatment in patients with Behcets’ disease (BD). Twenty-seven eyes of 20 patients (12 males and eight females)...The role of inflammation in the pathophysiology of DMO
Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...The management of retinal vein occlusions: a summary
Retinal vein occlusions (RVO) are the most common cause of visual loss from retinal vascular disease second to diabetic retinopathy. Vision is lost due to ischaemia, macular oedema and / or haemorrhage which ultimately effects a patient’s quality of life...NICE drugs: an update on what’s good to go
Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...Aspiration of anteriorly migrated dexamethasone implant using an 18G intravenous cannula
Intravitreal dexamethasone (Ozurdex 0.7mg) is a biodegradable, sustained-release implant used to manage diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and non-infectious posterior uveitis due to its anti-inflammatory effects and VEGF suppression [1]. While effective, the implant may...
